{"schema_version":"1","generated_at":"2026-10-31T19:58:34.205Z","data_as_of":null,"url":"https://www.findmykol.com/kol/biree-andemariam","json_url":"https://www.findmykol.com/kol/biree-andemariam/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"biree-andemariam","name":"Biree Andemariam","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of Connecticut","institution_url":"https://www.findmykol.com/institution/university-of-connecticut","city":"Farmington","state":"CT","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1396935136","orcid":"0000-0002-2540-6037","openalex":"A5088205989"},"summary":"Biree Andemariam is an Oncology physician affiliated with University of Connecticut. OpenAlex indexes 180 publications with 2,139 citations (h-index 23); ClinicalTrials.gov lists 3 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":180,"cited_by_count":2139,"h_index":23,"latest_activity_year":2025,"source":"works"},"trials":{"count":3,"shown":3,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT07083531","title":"Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait","status":"RECRUITING","role":"Overall official","sponsor":"UConn Health","source_url":"https://clinicaltrials.gov/study/NCT07083531","trial_url":"https://www.findmykol.com/trial/NCT07083531"},{"nct":"NCT06743113","title":"Hypoxic Red Blood Cells in Sickle Cell Anemia","phase":"NA","status":"NOT_YET_RECRUITING","role":"Overall official","sponsor":"Hemanext","source_url":"https://clinicaltrials.gov/study/NCT06743113","trial_url":"https://www.findmykol.com/trial/NCT06743113"},{"nct":"NCT02306993","title":"Sickle Cell Hemoglobinopathies and Bone Health","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"UConn Health","source_url":"https://clinicaltrials.gov/study/NCT02306993","trial_url":"https://www.findmykol.com/trial/NCT02306993"}],"source":"trials"},"payments":{"company_count":22,"program_years":{"first":2021,"last":null},"rows_total":43,"shown":3,"withheld":40,"rows":[{"payer":"Agios Pharmaceuticals, Inc.","program_year":2025,"amount_usd":56147.35,"payment_count":27,"source_url":"https://openpaymentsdata.cms.gov/search?query=1396935136"},{"payer":"PFIZER INC.","program_year":2025,"amount_usd":31035.96,"payment_count":11,"source_url":"https://openpaymentsdata.cms.gov/search?query=1396935136"},{"payer":"Novo Nordisk Health Care AG","program_year":2025,"amount_usd":22131.25,"payment_count":6,"source_url":"https://openpaymentsdata.cms.gov/search?query=1396935136"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1396935136","source":"payments"},"prescribing":{"data_year":2020,"areas_total":1,"areas_shown":1,"areas":[{"area":"Blood & clotting","share_pct":100,"classes_total":1,"classes":[{"class":"Hemoglobin S Polymerization Inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Oxbryta","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2020,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial","year":2024,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(24)00319-3","status":"verified"},{"title":"Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States","year":2024,"journal":"PharmacoEconomics","source_url":"https://doi.org/10.1007/s40273-024-01385-9","status":"verified"},{"title":"Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks","year":2024,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2024-204962","status":"verified"},{"title":"Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission","year":2023,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(23)00096-0","status":"verified"},{"title":"Economic and clinical burden of managing transfusion-dependent β-thalassemia in the United States","year":2023,"journal":"Journal of Medical Economics","source_url":"https://doi.org/10.1080/13696998.2023.2235928","status":"verified"}],"source":"works"},"contact":{"address_1":"263 FARMINGTON AVE","city":"Farmington","state":"CT","zip":"060300001","phone":"860-679-2100","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1396935136","source":"identity"},"similar":[{"name":"Andrew Winokur","slug":"andrew-winokur","institution":"University of Connecticut","specialty":"Psychiatry","url":"https://www.findmykol.com/kol/andrew-winokur","json_url":"https://www.findmykol.com/kol/andrew-winokur/profile.json"},{"name":"Martha Radford","slug":"martha-radford","institution":"University of Connecticut","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/martha-radford","json_url":"https://www.findmykol.com/kol/martha-radford/profile.json"},{"name":"Hardik Dineshbhai Desai","slug":"hardik-desai","institution":"University of Connecticut","url":"https://www.findmykol.com/kol/hardik-desai","json_url":"https://www.findmykol.com/kol/hardik-desai/profile.json"},{"name":"Ching Lau","slug":"ching-lau","institution":"University of Connecticut","specialty":"Pediatric Hematology-Oncology","url":"https://www.findmykol.com/kol/ching-lau","json_url":"https://www.findmykol.com/kol/ching-lau/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":40,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-09-26","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2020}},"methodology_url":"https://www.findmykol.com/about#methodology"}